Investment analysts at Guggenheim began coverage on shares of Novogen (NASDAQ:KZIA – Get Free Report) in a research report issued on Wednesday, Briefing.com reports. The brokerage set a “buy” rating and a $35.00 price target on the stock. Guggenheim’s target price indicates a potential upside of 344.16% from the company’s previous close.
KZIA has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research note on Thursday, October 15th. Leerink Partners initiated coverage on Novogen in a research note on Tuesday. They set an “outperform” rating and a $30.00 price objective on the stock. Canaccord Genuity Group initiated coverage on Novogen in a research note on Thursday, August 13th. They set a “buy” rating and a $29.00 price objective on the stock. Finally, BTIG Research reissued a “buy” rating and issued a $40.00 price objective on shares of Novogen in a report on Thursday, September 10th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Novogen has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.
Check Out Our Latest Stock Report on Novogen
Novogen Stock Up 0.4%
NASDAQ:KZIA opened at $7.88 on Wednesday. Novogen has a 52-week low of $4.86 and a 52-week high of $17.40. The stock’s 50-day simple moving average is $11.07 and its 200 day simple moving average is $11.99.
About Novogen
Novogen Limited was an Australian biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research centered on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival.
Novogen’s oncology programs included investigational treatments such as Cantrixil, a therapy intended to target cancer stem cells, and Trilexium, an anticancer compound based on a DNA-damaging mechanism. The company also developed brain-penetrant compounds for the treatment of central nervous system cancers.
In 2016, Novogen changed its name to Kazia Therapeutics Limited and adopted the Nasdaq symbol KZIA.
Further Reading
- Five stocks we like better than Novogen
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.
